Irenaeus, Sandra
Hellström, Vivan http://orcid.org/0000-0003-4949-3267
Wenthe, Jessica http://orcid.org/0000-0003-4385-7568
Krause, Johan
Sundin, Anders
Ahlström, Håkan
Tufveson, Gunnar
Tötterman, Thomas H.
Loskog, Angelica http://orcid.org/0000-0001-8583-6138
Ullenhag, Gustav J.
Funding for this research was provided by:
Stiftelsen Onkologiska Kliniken i Uppsala Forskningsfond. Lion’s Cancer Fund at Uppsala University Hospital.
Cancerfonden (Swedish Cancer Society. Lion’s Cancer Fund at Uppsala University Hospital.
Swedish Cancer Society. Medical Faculty at Uppsala University. Swedish State Support for Clinical Research. Lion’s Cancer Fund at Uppsala University Hospital.
Article History
Received: 11 June 2020
Revised: 7 November 2020
Accepted: 23 November 2020
First Online: 14 December 2020
Compliance with ethical standards
:
: Dr Loskog is the CEO and board member of Lokon Pharma AB. She also holds a research grant from Lokon Pharma AB. Dr Loskog is a scientific advisor and alternate board member of NEXTTOBE AB. She is the founder of Lynxalo AB and has a royalty agreement with Alligator Bioscience AB. Dr Totterman has a royalty agreement and is an advisor to Alligator Bioscience AB. Håkan Ahlström is one of the founders and employee of Antaros Medical AB, Bioventure Hub, Mölndal, Sweden. The remaining authors declare no financial conflict of interest.